VeloGene Biotechnology-TurboMice™

The Next Generation Mouse Model Preparation Technology

Guangzhou MingCeler Biotech Signs Strategic MOU with Hankook Kinetico Engineering in South Korea to Roll Out Custom Gene-Edited Mouse Models

16/Jun/2026

Guangzhou MingCeler Biotech Co., Ltd. (“MingCeler Biotech”) has officially signed a strategic Memorandum of Understanding (MOU) with Daegu-based Hankook Kinetico Engineering of the Republic of Korea on June 16, 2026. The signing ceremony was witnessed by Dr. Wu Guangming, President & CEO of MingCeler Biotech, and Mr. OH, Jae Wan, President & CEO of Hankook Kinetico Engineering, marking the launch of a formal strategic cooperation between the two enterprises.
 
The MOU establishes a long-term cooperative framework centered on customized gene-edited mouse disease models, tailored to meet the research demands of South Korea’s biomedical research community. Under this partnership, MingCeler Biotech will leverage its proprietary innovative technology platforms to deliver high-standard custom mouse disease model solutions, while Hankook Kinetico Engineering will serve as the preferred local partner to advance market deployment across South Korea.
我方2(1)
韩方1(1)
我方1(1)
韩方2(1)

The collaboration covers custom gene-edited mouse disease models including knockout, knock-in, conditional knockout and humanized strains. MingCeler will leverage its exclusive TurboMice M and tetraploid complementation technologies to speed up model development, with all animals raised in AAALAC-certified facilities and full QC reports supplied for each batch. Full technical services will also be offered to local research teams.

Hankook Kinetico Engineering will collect local research demands, manage import, customs, sales and distribution across South Korea, and share user feedback to support product upgrades. It obtains priority rights to market and sell MingCeler’s mouse models nationwide. Pricing, order quantities, delivery and logistics will be settled in a separate formal contract later.

Both parties hold positive prospects for long-term joint development. Going forward, the two companies will carry out follow-up commercial negotiations based on the MOU framework. With complementary strengths, they will jointly expand the market of custom gene-edited mouse disease models in South Korea, support local life science research and preclinical drug research, and realize stable win-win development through continuous in-depth cooperation.